Foretinib (phosphate)

CAT: 0804-HY-10338ASize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-10338ASize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB[1].
CAS Number
[1226999-07-0]
UNSPSC
12352005
Target
C-Met/HGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/foretinib-phosphate.html
Smiles
O=C(C1(CC1)C(NC2=CC=C(C(F)=C2)OC3=C4C=C(OC)C(OCCCN5CCOCC5)=CC4=NC=C3)=O)NC6=CC=C(C=C6)F.O=P(O)(O)O.O=P(O)(O)O
Molecular Formula
C34H40F2N4O14P2
Molecular Weight
828.64
References & Citations
[1]Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 2009, 69 (20), 8009-8016.|[2]Kataoka Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs, 2011.|[3]Eder JP, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res, 2010, 16 (13), 3507-3516.|[4]Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
VEGFR2/KDR/Flk-1